• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.

作者信息

Drake Marcus J, Birder Lori A

机构信息

Department of Surgery and Cancer, Imperial College London, London, UK.

University of Pittsburgh Department of Medicine, Pittsburgh, PA, USA.

出版信息

Eur Urol. 2024 Aug;86(2):183-184. doi: 10.1016/j.eururo.2024.03.011. Epub 2024 Mar 26.

DOI:10.1016/j.eururo.2024.03.011
PMID:38538426
Abstract
摘要

相似文献

1
Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.关于：EV-301长期结果：恩杂鲁胺与化疗用于既往治疗过的晚期尿路上皮癌患者的III期试验的24个月结果
Eur Urol. 2024 Aug;86(2):183-184. doi: 10.1016/j.eururo.2024.03.011. Epub 2024 Mar 26.
2
The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.恩杂鲁胺和帕博利珠单抗在晚期尿路上皮癌患者中的临床应用：基于治疗标准运用临床判断
ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.
3
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?EV-302 研究中的总生存获益：恩福妥单抗维迪西妥单抗联合帕博利珠单抗是否成为转移性尿路上皮癌的新标准？
Eur Urol Oncol. 2024 Jun;7(3):313-315. doi: 10.1016/j.euo.2024.02.010. Epub 2024 Mar 13.
4
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?恩福妥单抗和帕博利珠单抗联合治疗在尿路上皮癌中的相关变革：还有什么遗留问题？
Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.
5
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):283. doi: 10.1016/j.eururo.2024.05.001. Epub 2024 May 13.
6
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):282-283. doi: 10.1016/j.eururo.2024.03.032. Epub 2024 Apr 16.
7
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺与帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):280-281. doi: 10.1016/j.eururo.2024.03.029. Epub 2024 Apr 9.
8
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.先前接受过治疗的晚期尿路上皮癌患者的健康相关生活质量来自 EV-301：恩福妥单抗 Vedotin 与化疗的 3 期试验。
Eur Urol. 2024 Jun;85(6):574-585. doi: 10.1016/j.eururo.2024.01.007. Epub 2024 Feb 28.
9
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.欧洲肿瘤内科学会（ESMO）晚期尿路上皮癌一线治疗临床实践指南临时更新
Ann Oncol. 2024 Jun;35(6):485-490. doi: 10.1016/j.annonc.2024.03.001. Epub 2024 Mar 13.
10
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.恩杂鲁胺和帕博利珠单抗作为转移性尿路上皮癌新的一线标准治疗方案。
Med. 2024 Feb 9;5(2):106-108. doi: 10.1016/j.medj.2023.11.010. Epub 2023 Dec 20.